Sanofi to Reach Full Commercial Control of the Antibody Beyfortus (nirsevimab) against RSV in the U.S.

Sanofi Commercial Control of Beyfortus Against RSV
In the morning, we promised to tell our readers how AstraZeneca's (AZN), Sobi, and Sanofi (

Please click here to subscribe or here to log in.